{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:25:03Z","timestamp":1785169503346,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study investigated the factors predicting survival and the recurrence of pericardial effusion (PE) requiring pericardiocentesis (PCC) in patients with cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We analyzed the data of patients who underwent PCC for large PEs from 2010 to 2020 at The University of Texas MD Anderson Cancer Center. The time to the first recurrent PE requiring PCC was the interval from the index PCC with pericardial drain placement to first recurrent PE requiring drainage (either repeated PCC or a pericardial window). Univariate and multivariate Fine-Gray models accounting for the competing risk of death were used to identify predictors of recurrent PE requiring drainage. Cox regression models were used to identify predictors of death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study cohort included 418 patients with index PCC and pericardial drain placement, of whom 65 (16%) had recurrent PEs requiring drainage. The cumulative incidences of recurrent PE requiring drainage at 12 and 60 months were 15.0% and 15.6%, respectively. Younger age, anti-inflammatory medication use, and solid tumors were associated with an increased risk of recurrence of PE requiring drainage, and that echocardiographic evidence of tamponade at presentation and receipt of immunotherapy were associated with a decreased risk of recurrence. Factors predicting poor survival included older age, malignant effusion on cytology, non-use of anti-inflammatory agents, non-lymphoma cancers and primary lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among cancer patients with large PEs requiring drainage, young patients with solid tumors were more likely to experience recurrence, while elderly patients and those with lung cancer, malignant PE cytology, and non-use of anti-inflammatory agents showed worse survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.916325","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:24:26Z","timestamp":1653971066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis"],"prefix":"10.3389","volume":"9","author":[{"given":"Talha","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Mouhayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Wamique","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saamir A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Cilingiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2015.06.1332","article-title":"Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion.","volume":"66","author":"El Haddad","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pcad.2010.06.003","article-title":"Evaluation and management of pericardial effusion in patients with neoplastic disease.","volume":"53","author":"Maisch","year":"2010","journal-title":"Prog Cardiovasc Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/heartjnl-2015-307907","article-title":"Systematic review of percutaneous interventions for malignant pericardial effusion.","volume":"101","author":"Virk","year":"2015","journal-title":"Heart."},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4065\/75.3.248","article-title":"Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy.","volume":"75","author":"Tsang","year":"2000","journal-title":"Mayo Clin Proc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4143\/crt.2010.42.4.210","article-title":"Clinical characteristics of malignant pericardial effusion associated with recurrence and survival.","volume":"42","author":"Kim","year":"2010","journal-title":"Cancer Res Treat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.chest.2017.11.003","article-title":"Tamponade: hemodynamic and echocardiographic diagnosis.","volume":"153","author":"Kearns","year":"2018","journal-title":"Chest."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.638943","article-title":"Prognostic factors and overall survival after pericardiocentesis in patients with cancer and thrombocytopenia.","volume":"8","author":"Wilson","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2016.05.068","article-title":"Echocardiography and fluoroscopy-guided pericardiocentesis for cancer patients with cardiac tamponade and thrombocytopenia.","volume":"68","author":"Iliescu","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting fine-gray model analyses for competing risk data.","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0962280210394479","article-title":"Practical methods for competing risks data: a review.","volume":"21","author":"Bakoyannis","year":"2012","journal-title":"Stat Methods Med Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.amjcard","article-title":"Safety and outcome of percutaneous drainage of pericardial effusions in patients with cancer.","volume":"122","author":"Lekhakul","year":"2018","journal-title":"Am J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/icvts\/ivu267","article-title":"Palliative treatment for symptomatic malignant pericardial effusion\u2020.","volume":"19","author":"Jama","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.09.051","article-title":"Prognostic implications of pericardial effusion: the importance of underlying etiology.","volume":"202","author":"Santas","year":"2016","journal-title":"Int J Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehs372","article-title":"Management of pericardial effusion.","volume":"34","author":"Imazio","year":"2013","journal-title":"Eur Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.jacc.2020.08.003","article-title":"Effect of anti-inflammatory drugs on clinical outcomes in patients with malignant pericardial effusion.","volume":"76","author":"Kim","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","article-title":"Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial.","volume":"383","author":"Imazio","year":"2014","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007598","article-title":"Etiology and long-term outcome of patients undergoing pericardiocentesis.","volume":"6","author":"Strobbe","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1200\/JCO.2005.00.745","article-title":"Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion.","volume":"23","author":"Gornik","year":"2005","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cncy.21246","article-title":"Pericardial fluid cytology: an analysis of 128 specimens over a 6-year period.","volume":"121","author":"Dragoescu","year":"2013","journal-title":"Cancer Cytopathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncy.21790","article-title":"Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens.","volume":"125","author":"Saab","year":"2017","journal-title":"Cancer Cytopathol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes.","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1245\/s10434-008-0059-z","article-title":"Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival.","volume":"15","author":"Dequanter","year":"2008","journal-title":"Ann Surg Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.amjcard.2013.05.066","article-title":"Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy.","volume":"112","author":"Patel","year":"2013","journal-title":"Am J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.amjcard.2017.06.003","article-title":"Comparison of outcomes of pericardiocentesis versus surgical pericardial window in patients requiring drainage of pericardial effusions.","volume":"120","author":"Horr","year":"2017","journal-title":"Am J Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European society of cardiology (ESC) endorsed by: the European association for cardio-thoracic surgery (EACTS).","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jaccao.2021.05.005","article-title":"How to perform pericardiocentesis in cancer patients with thrombocytopenia: a single-center experience.","volume":"3","author":"Jacob","year":"2021","journal-title":"J Am Coll Cardiol CardioOncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2459\/JCM.0000000000000649","article-title":"Evolution of the pericardiocentesis technique.","volume":"19","author":"Maggiolini","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s11739-021-02642-x","article-title":"Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes.","volume":"16","author":"Pennacchioni","year":"2021","journal-title":"Intern Emerg Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.916325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:24:28Z","timestamp":1653971068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.916325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2022.916325"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.916325","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"916325"}}